LINE-1 Deregulation in Ovarian Cancer: Implications for Diagnosis, Prognosis, and Therapeutic Targeting
Jumping genes in ovarian cancer show potential as blood biomarkers and drug targets, sitting at the intersection of tumor genetics and immunity.
Review of LINE-1 retrotransposon deregulation in ovarian cancer evaluates its potential as a minimally invasive cfDNA epigenetic biomarker and therapeutic target, positioned at the intersection of HRD and immune activation. Deferred from the prior run's liquid biopsy article set.
What the study was
- Study design
- Narrative review
- Population
- Ovarian cancer patients
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Molecular Diagnosis and Therapy
Why it surfaced
Deferred from 2026-06-12 run; cfDNA epigenetic biomarker for ovarian cancer — high unmet early-detection need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.